CHIMIN HEALTH MANAGEMENT CO., LTD. Chimin Health Management Co., Ltd. Stock
Equities
603222
CNE100002193
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.94 CNY | +3.30% |
|
+6.26% | -25.84% |
| Sales 2022 | 837M 116M | Sales 2023 | 895M 123M | Capitalization | 4.26B 587M |
|---|---|---|---|---|---|
| Net income 2022 | 34M 4.69M | Net income 2023 | -65M -8.97M | EV / Sales 2022 | 4.93 x |
| Net cash position 2022 | 49.5M 6.83M | Net Debt 2023 | 119M 16.37M | EV / Sales 2023 | 4.89 x |
| P/E ratio 2022 |
125
x | P/E ratio 2023 |
-66.8
x | Employees | 1,851 |
| Yield 2022 |
0.23% | Yield 2023 |
-
| Free-Float | 54.13% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.30% | ||
| 1 week | +6.26% | ||
| Current month | -5.41% | ||
| 1 month | -8.05% | ||
| 3 months | -15.62% | ||
| 6 months | -36.33% | ||
| Current year | -25.84% |
1 week
5.35
6.11
1 month
5.346.68
Current year
4.708.12
1 year
4.7013.02
3 years
4.7016.28
5 years
4.7041.07
10 years
3.7941.07
| Managers | Title | Age | Since |
|---|---|---|---|
Yun Fei Tian
PSD | President | 44 | 08-03-31 |
Lian Lan Wang
CTO | Chief Tech/Sci/R&D Officer | 47 | 22-11-14 |
Kun Chen
BRD | Director/Board Member | 42 | 18-04-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kai Tian Wang
BRD | Director/Board Member | 67 | 19-10-15 |
Li Sha Li
CHM | Chairman | 46 | - |
Yun Fei Tian
PSD | President | 44 | 08-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 5.94 | +3.30% | 10,905,720 |
| 24-04-25 | 5.75 | +0.70% | 6,279,240 |
| 24-04-24 | 5.71 | +0.53% | 6,699,540 |
| 24-04-23 | 5.68 | +2.16% | 6,844,700 |
| 24-04-22 | 5.56 | +1.46% | 6,704,857 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Chimin Health Management Co., Ltd., formerly Zhejiang Chimin Pharmaceutical CO., Ltd, is primarily engaged in the research, development, manufacture and sale of infusion and injection and puncture machinery products. The Company primarily produces Non Polyvinyl chloride (PVC) soft bag infusion products, plastic bottle infusion products, as well as injection and puncture machinery products, including safety syringe, sterile syringes and infusion sets. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.84% | 422M | |
| +11.84% | 27.91B | |
| -32.98% | 2.95B | |
| -15.97% | 2.47B | |
| +11.90% | 2.22B | |
| -1.11% | 1.91B | |
| -13.37% | 1.84B | |
| -7.78% | 1.4B | |
| -0.38% | 1.26B | |
| +13.51% | 1.13B |
- Stock Market
- Equities
- 603222 Stock
